Sionna Therapeutics, Inc. (SION)

NASDAQ: SION · Real-Time Price · USD
20.28
+0.42 (2.11%)
Feb 13, 2025, 7:43 PM EST - Market closed
2.11%
Market Cap 862.32M
Revenue (ttm) n/a
Net Income (ttm) -57.72M
Shares Out 42.52M
EPS (ttm) -16.77
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 144,269
Open 20.24
Previous Close 19.86
Day's Range 19.49 - 21.04
52-Week Range 19.26 - 25.19
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About SION

Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients. Our goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide-binding d... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 7, 2025
Employees 28
Stock Exchange NASDAQ
Ticker Symbol SION
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

Sionna Therapeutics Announces Closing of $219.2 million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

BOSTON, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic f...

3 days ago - GlobeNewsWire

U.S. IPO Weekly Recap: Cement And Cystic Fibrosis Drugs Lead A 6 IPO Week

Two sizable companies and a handful of small Asian issuers were listed in the US this past week. Four small Asia-based issuers also went public in the US - EPWK Holdings, FBS Global, Plutus Financial ...

5 days ago - Seeking Alpha

Sionna Therapeutics Prices Upsized Initial Public Offering

BOSTON, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fi...

7 days ago - GlobeNewsWire

U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs

Five IPOs listed this week, all of which raised over $100 million; one direct listing and three SPACs also debuted. Four microcaps submitted initial filings this week - Vistek, Awaysis Capital, QMSK T...

12 days ago - Seeking Alpha

Sionna Therapeutics Seeks $100 Million in IPO For Cystic Fibrosis Treatments

Sionna Therapeutics aims to raise $100 million in an IPO to advance its cystic fibrosis drug candidates, currently in Phase 1 and Phase 2 trials. The firm is well-capitalized with $137.5 million in ca...

20 days ago - Seeking Alpha

Cystic fibrosis biotech Sionna Therapeutics files for a $100 million IPO

Sionna Therapeutics, a Phase 2 biotech developing novel therapies for cystic fibrosis, filed on Friday with the SEC to raise up to an estimated $100 million in an initial public offering.

27 days ago - Renaissance Capital

Sionna Therapeutics IPO Registration Document (S-1)

Sionna Therapeutics has filed to go public with an IPO on the NASDAQ.

27 days ago - SEC